Tachyon’s VC round, CIRM grant drive first-in-class oncology program to clinic

A well-traveled epigenetic program for oncology that originated at Quanticel has finally reached the clinic in the hands of Tachyon, which is deploying a grant from CIRM and a modest venture round to develop first-in-class KDM4 inhibitor TACH101.

Tachyon Therapeutics Inc. said Wednesday that the first patient had been enrolled in a Phase I study of TACH101 to treat advanced solid tumors, with a focus on gastrointestinal cancers including microsatellite instability-high (MSI-H) colorectal cancer...